Kuros Biosciences AG
CSBTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 125.1% | 86.6% | 30.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.1% | 84.8% | 59.9% | 72.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.7% | -22.3% | -41.7% | -38.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4.9% | -40.9% | -81.1% | -54.6% |
| EPS Diluted | -0.1 | -0.38 | -0.43 | -0.23 |
| % Growth | 73.7% | 11.6% | -87% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |